Stanley Hazen, M.D., Ph.D.
| Appointed: |
1997 |
| Gender: |
Male |
| Languages: |
English |
Cardiovascular Medicine
Section Head, Preventive Cardiology
Cell Biology
Biographical Sketch
Stanley Hazen, MD, PhD, is the Head of the Section for Preventive Cardiology and Rehabilitation, Director for the Center for Cardiovascular Diagnostics and Prevention, and he is a Staff Physician in the Department of Cell Biology and the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at Cleveland Clinic.
Dr. Hazen is board-certified as a Diplomat of the American Board of Internal Medicine. He has also completed subspecialty training in endocrinology, diabetes and metabolism. He sees patients within the Preventive Cardiology Clinic, specializing in care of patients with hyperlipidemia, diabetes and hypertension, as well as within the Cardiovascular Rehabilitation program. His research interests include understanding the role of inflammation and oxidant stress in the pathogenesis of atherosclerosis and other inflammatory diseases. He is an expert in mechanisms of atherosclerosis, the biochemistry of leukocyte peroxidases, free radicals and reactive oxygen species and mechanisms of oxidative damage.
He has published over 180 peer-reviewed articles, invited reviews and book chapters in the fields of atherosclerosis, oxidation and inflammation chemistry, and cardiovascular disease. He has received many honors and awards for his research work, which has contributed to new understandings of inflammation in cardiovascular disease and the development of new diagnostic and treatment tools. He is listed as a co-inventor on multiple patents for his work in identifying patients at increased risk for cardiovascular disease, diagnosing asthma, and treating inflammation and associated complications. He has been principal investigator on numerous National Institutes of Health grants and research awards related to his specialty interests.
He serves as reviewer for more than 20 scientific journals including Circulation, Analytical Biochemistry, Journal of Clinical Investigation, Journal of Biological Chemistry and the Journal of Lipid Research. Dr. Hazen serves on the editorial board of Circulation, The Journal of Biological Chemistry and Free Radicals in Biology & Medicine. He has been invited to lecture at national and international symposia and conferences in both basic science and clinical fields alike, as well as workshops held by the National Heart, Lung and Blood Institutes (National Institutes of Health) on mechanisms of atherogenesis, pulmonary immunobiology and inflammation, the origins of asthma, and nitric oxide biology.
Dr. Hazen is a member of the American Society for Clinical Investigation, the American Association of Physicians, a fellow of the American Association for the Advancement of Science, the American College of Physicians, the American Federation for Medical Research, the American Heart Association Scientific Council for Arteriosclerosis, the American Medical Association, the American Society for Mass Spectrometry, the International Society for Free Radical Research, the Society for Free Radical Biology & Medicine, and the American Society for Investigative Pathology.
Professional Highlights
- Chair, Gordon Research Conference on Oxygen Radicals
- Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular Biology Award for Basic Science and Clinical Research
- Election, Association of American Physicians (AAP)
- Election, Fellow of American Heart Association Scientific Council for Arteriosclerosis
- Election, American Society for Clinical Investigation
Education & Fellowships
| Medical School: | Washington University School of Medicine, St. Louis, MO |
|
| Residency: | Barnes-Jewish Hospital, Internal Medicine, St. Louis, MO |
| Fellowship: | Barnes-Jewish Hospital, Endocrinology, St. Louis, MO |
| Other Education: | (Doctorate) Washington University, St. Louis, MO |
| Other Education: | (Undergraduate) Washington University, St. Louis, MO |
Specialty Interests
Preventive cardiology, cardiac rehabilitation, cardiovascular risk evaluation, prevention, wellness, preventive medicine, cholesterol, CRP, LDL, HDL, triglycerides.
Innovations & Patents
- Patent Title: Diagnostic Methods for Asthma; U.S. Serial Number 09/253,380
- Patent Title: Myeloperoxidase, a Risk Indicator for Cardiovascular Disease; U.S., Serial Number 10/039,753
- Patent Title: Treating Inflammation and Associated Complications; Patent Reference Number 09531-030P01 (Pending)
- Patent Title: Methods of Identifying Subjects at Increased Risk for Cardiovascular Disease; U.S. Serial Number 60/259,340 (Pending)
- Patent Title: Monitoring Anti-inflammatory and Anti-oxidant Actions of Therapies; U.S. Serial Number (Pending)
- Patent Title: Diagnostic Method for Identifying Subjects at Risk for Atherosclerosis and its Complications; U.S. Serial Number (Pending)
Awards & Honors
- Howard Hughes Medical Institute Research Fellowship for Physicians Award, 1995-1997
- AAP, ASCI, and AFMR Certificate of Achievement Award, 1997
- Marilyn Hansen American Thoracic Society Award, 1997
- Junior Faculty Award, American Federation of Medical Research, 1999
- Gill Heart Institute Physician Scientist Award, University of Kentucky, Lexington Ky., 2001
- Election, American Society for Clinical Investigation, 2003
- John J. Ferchill Award for Innovation, Cleveland Clinic, 2004
- Nomination, Howard Hughes Medical Institute Investigator Award, 2004
- Vice-Chair, Gordon Research Conference on Oxygen Radicals, 2006
- Jeffrey M Hoeg Arteriosclerosis, Thrombosis and Vascular, 2007
Professional Memberships
- American Society for Clinical Investigation
- American Association for the Advancement of Science
- American Heart Association Scientific Council for Arteriosclerosis
- American Society for Investigative Pathology
- American College of Cardiology
Specializes in Diseases and Conditions
Specializes in Services
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 9/5/2008, Dr. Hazen has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
Consulting. Dr. Hazen receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:
- AstraZeneca Pharmaceuticals LP
- BG Medicine, Inc.
- Biophysical Corporation
- Merck & Co., Inc.
- Merck/Schering-Plough Pharmaceuticals
- Pfizer Inc.
- PrognostiX, Inc.
- Wyeth Pharmaceuticals Inc.
Royalty Payments. Dr. Hazen has the right to receive royalty payments for inventions or discoveries related to the companies shown below:
- Abbott Laboratories, Inc.
- Biosite Incorporated
- Frantz Biomarkers, LLC
- Siemens
Inventor Share. Dr. Hazen may receive future financial benefits from the Cleveland Clinic for inventions or discoveries related to the companies shown below:
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
